Insight

Udhayvir Grewal: Real world post-marketing pharmacovigilance analysis on hematological toxicities in the US

Photo taken from Udhayvir Grewal/X

Jun 10, 2024, 10:02

Udhayvir Grewal: Real world post-marketing pharmacovigilance analysis on hematological toxicities in the US

Udhayvir Grewal, Resident Physician at Ochsner LSU Health Shreveport, recently shared a post on X:

“Hot off the press.

Happy to share our real-world post-marketing pharmacovigilance analysis on hematological toxicities (focus on MDS/AML) with Lutathera (Lu177-DOTA-TATE) in the US.

Post-marketing surveillance data from the U.S. FDA (2018-2023)
3443 adverse events, 243 (7.1%) were hematologic
Majority thrombocytopenia, leukopenia, anemia, and pancytopenia
MDS and AML comprised 2% of the reported events each.
For context, we compare the reporting of hematological toxicities (esp MDS and AML) with topoisomerase inhibitors
This is a helpful reference that may potentially inform discussions with patients planning to receive PRRT (now referred to as radioligand therapy or RLT).

Limitations – captures only the US data and the events reported to the U.S. FDA.

Thank you Anuj Thakre for your help with the project.”

Udhayvir Grewal: Real world post-marketing pharmacovigilance analysis on hematological toxicities in the US

Read further
Source: Udhayvir Grewal/X

anemia Anuj Thakre cancer hematological toxicities leukopenia Lu177-DOTA-TATE Lutathera MDS/AML OncoDaily Oncology pancytopenia PRRT radioligand therapy RLT Thrombocytopenia topoisomerase inhibitors U.S. FDA Udhayvir Grewal

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Former Disney CEO Bob Chapek Appointed Senior Adviser at SCAN Group

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage